E. Kutarska

1.2k total citations · 1 hit paper
17 papers, 939 citations indexed

About

E. Kutarska is a scholar working on Reproductive Medicine, Molecular Biology and Oncology. According to data from OpenAlex, E. Kutarska has authored 17 papers receiving a total of 939 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Reproductive Medicine, 5 papers in Molecular Biology and 5 papers in Oncology. Recurrent topics in E. Kutarska's work include Ovarian cancer diagnosis and treatment (14 papers), Cancer, Lipids, and Metabolism (5 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). E. Kutarska is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Cancer, Lipids, and Metabolism (5 papers) and Intraperitoneal and Appendiceal Malignancies (4 papers). E. Kutarska collaborates with scholars based in Poland, United States and United Kingdom. E. Kutarska's co-authors include P. Koralewski, Angelika Lahr, M. M. Heiss, P. Murawa, Alexander Burges, Pauline Wimberger, Alexander S. Dudnichenko, В. В. Іванченко, Martin Gore and Horst Lindhofer and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

E. Kutarska

17 papers receiving 917 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

2010 405 citations M. M. Heiss, P. Murawa et al. International Journal of Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Kutarska Poland	12	440	285	274	211	200	17	939
Renata Tassi Italy	20	341 0.8×	503 1.8×	394 1.4×	192 0.9×	85 0.4×	30	1.3k
Mildred Felder United States	17	421 1.0×	145 0.5×	445 1.6×	467 2.2×	109 0.5×	39	1.1k
Huiying Piao United States	10	442 1.0×	160 0.6×	715 2.6×	98 0.5×	94 0.5×	10	1.2k
V. Heilmann Germany	15	342 0.8×	81 0.3×	200 0.7×	109 0.5×	209 1.0×	32	870
Biagio Paolini Italy	20	305 0.7×	188 0.7×	325 1.2×	97 0.5×	53 0.3×	80	1.0k
Els Van Nieuwenhuysen Belgium	20	559 1.3×	630 2.2×	372 1.4×	180 0.9×	42 0.2×	99	1.3k
Delicia Carey United States	15	596 1.4×	113 0.4×	491 1.8×	139 0.7×	221 1.1×	21	1.2k
Yuri Matsumoto Japan	22	675 1.5×	245 0.9×	324 1.2×	494 2.3×	50 0.3×	53	1.3k
Steve Gyorffy Canada	14	258 0.6×	102 0.4×	242 0.9×	195 0.9×	27 0.1×	18	798
A. Berchuck United States	21	337 0.8×	673 2.4×	417 1.5×	117 0.6×	54 0.3×	42	1.4k

Countries citing papers authored by E. Kutarska

Since Specialization

Citations

This map shows the geographic impact of E. Kutarska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Kutarska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Kutarska more than expected).

Fields of papers citing papers by E. Kutarska

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Kutarska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Kutarska. The network helps show where E. Kutarska may publish in the future.

Co-authorship network of co-authors of E. Kutarska

This figure shows the co-authorship network connecting the top 25 collaborators of E. Kutarska. A scholar is included among the top collaborators of E. Kutarska based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Kutarska. E. Kutarska is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Ledermann, Jonathan A., Bogdan Żurawski, Francesco Raspagliesi, et al.. (2021). Maintenance therapy of patients with recurrent epithelial ovarian carcinoma with the anti-tumor-associated-mucin-1 antibody gatipotuzumab: results from a double-blind, placebo-controlled, randomized, phase II study. ESMO Open. 7(1). 100311–100311. 14 indexed citations

Kutarska, E., et al.. (2018). Retrospective Analysis of Intravaginal Brachytherapy in Adjuvant Treatment of Early Endometrial Cancer. BioMed Research International. 2018. 1–9. 4 indexed citations

Ledermann, JA, Jalid Sehouli, Bogdan Żurawski, et al.. (2017). A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma. Annals of Oncology. 28. v626–v626. 13 indexed citations

Pautier, Patricia, Ignace Vergote, Florence Joly, et al.. (2016). A Phase 2, Randomized, Open-Label Study of Irosustat Versus Megestrol Acetate in Advanced Endometrial Cancer. International Journal of Gynecological Cancer. 27(2). 258–266. 32 indexed citations

Herzog, Thomas J., et al.. (2016). Adverse Event Profile by Folate Receptor Status for Vintafolide and Pegylated Liposomal Doxorubicin in Combination, Versus Pegylated Liposomal Doxorubicin Alone, in Platinum-Resistant Ovarian Cancer. International Journal of Gynecological Cancer. 26(9). 1580–1585. 9 indexed citations

Cybulski, Marek, Bożena Jarosz, Andrzej Nowakowski, et al.. (2015). Cyclin A correlates with YB1, progression and resistance to chemotherapy in human epithelial ovarian cancer.. PubMed. 35(3). 1715–21. 19 indexed citations

Naumann, R. Wendel, Robert L. Coleman, Robert A. Burger, et al.. (2013). PRECEDENT: A Randomized Phase II Trial Comparing Vintafolide (EC145) and Pegylated Liposomal Doxorubicin (PLD) in Combination Versus PLD Alone in Patients With Platinum-Resistant Ovarian Cancer. Journal of Clinical Oncology. 31(35). 4400–4406. 169 indexed citations

Symanowski, James T., E. Kutarska, Mariusz Bidziński, et al.. (2013). Adverse event profile by therapy cycle for vintafolide plus pegylated liposomal doxorubicin (PLD) versus PLD alone in platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 31(15_suppl). 5572–5572. 2 indexed citations

Colombo, Nicoletta, E. Kutarska, Meletios Α. Dimopoulos, et al.. (2012). Randomized, Open-Label, Phase III Study Comparing Patupilone (EPO906) With Pegylated Liposomal Doxorubicin in Platinum-Refractory or -Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian Tube, or Primary Peritoneal Cancer. Journal of Clinical Oncology. 30(31). 3841–3847. 95 indexed citations

10.

Matulonis, Ursula A., Sudarshan Sharma, Shekhar Ghamande, et al.. (2012). Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology. 127(1). 63–69. 111 indexed citations

11.

Pautier, Patricia, et al.. (2012). A Phase II Multicenter Randomized Open-Label Study of Oral Steroid Sulphatase (STS) Inhibitor Irosustat (BN83495) Versus Megestrol Acetate (MA) in Women with Advanced/Recurrent Endometrial Cancer (EC). Annals of Oncology. 23. ix329–ix329. 5 indexed citations

12.

Coleman, Robert L., Robert A. Burger, Thomas J. Herzog, et al.. (2011). PRECEDENT: A randomized phase II trial comparing EC145 and pegylated liposomal doxorubicin (PLD) in combination, versus PLD alone, in subjects with platinum-resistant ovarian cancer.. Journal of Clinical Oncology. 29(15_suppl). 5045–5045. 16 indexed citations

13.

Heiss, M. M., P. Murawa, P. Koralewski, et al.. (2010). The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. International Journal of Cancer. 127(9). 2209–2221. 405 indexed citations breakdown →

14.

Colombo, N., E. Kutarska, Charles H. Pippitt, et al.. (2009). Phase II study comparing volociximab (an antiangiogenic antibody) and pegylated liposomal doxorubicin (PLD) with PLD alone in recurrent ovarian or primary peritoneal cancer. Journal of Clinical Oncology. 27(15_suppl). 5560–5560. 17 indexed citations

15.

Murawa, P., P. Koralewski, E. Kutarska, et al.. (2008). Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study. Journal of Clinical Oncology. 26(15_suppl). 3000–3000. 16 indexed citations

16.

Parsons, S., et al.. (2007). 5001 ORAL Intraperitoneal administration of the trifunctional antibody catumaxomab for treatment of malignant ascites due to ovarian carcinoma: Results of a phase II/III study. European Journal of Cancer Supplements. 5(4). 311–311. 1 indexed citations

17.

Parsons, SL, E. Kutarska, P. Koralewski, et al.. (2007). Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study. Journal of Clinical Oncology. 25(18_suppl). 5520–5520. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact